Lanean...
Asenapine: A Review of Acute and Extension Phase Data in Bipolar Disorder
The second generation atypical antipsychotic, asenapine (Saphris), was approved by the US FDA (August 2009) for the acute treatment of manic or mixed episodes with or without psychotic features associated with bipolar I disorder in adults as well as the acute treatment of schizophrenia. Asenapine ex...
Gorde:
| Argitaratua izan da: | CNS Neurosci Ther |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Blackwell Publishing Ltd
2010
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6493886/ https://ncbi.nlm.nih.gov/pubmed/20950326 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1755-5949.2010.00200.x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|